TCM Life Sciences Signs Supply Contract for GainPad with Malaysian National Cancer Society

[Asia Economy Reporter Hyunseok Yoo] Molecular diagnostics company TCM biosciences announced on the 30th that it has signed a supply contract for GYNPAD with the National Cancer Society Malaysia (NCSM).

Through this contract, TCM biosciences will supply 10,000 GYNPADs to NCSM this year and 12,000 next year, with plans to discuss additional supplies in the future. Additionally, to conduct DNA testing for female diseases using GYNPAD locally, a tripartite memorandum of understanding (MOU) was signed with PANTAI Premier Pathology, the largest diagnostic testing center in Malaysia, and NCSM.

GYNPAD is the world's first pad-type female disease self-test kit. It is worn like a pantyliner for about 4 hours, and then the special filter is sent to a professional medical testing center, where it can diagnose infection with human papillomavirus (HPV), which causes cervical cancer, and sexually transmitted diseases (STDs).

NCSM is a national institution that conducts various programs from cancer research to prevention, diagnosis, and treatment in accordance with national health policies. Since the approval of GYNPAD as a medical device in Malaysia last August, discussions on various utilization methods have been held, and recently, the supply contract was signed amid the spread of the novel coronavirus disease (COVID-19) pandemic.

NCSM stated that it plans to actively utilize GYNPAD in medical settings facing difficulties such as avoidance of face-to-face consultations due to the impact of COVID-19. In major overseas countries including Malaysia, measures are being taken to notify individuals of auxiliary self-test results like those from GYNPAD via email, mobile applications, and other means.

A company official said, “In Islamic countries, due to religious and cultural reasons, it is difficult for women to undergo gynecological examinations, so there is high interest in GYNPAD, which allows convenient testing at home and result confirmation via email.” He added, “Especially recently, demand for non-face-to-face (untact) medical care has increased further due to COVID-19, so product sales are expected to be more active than originally planned.” He emphasized, “In the future, we will pursue medical device approval for GYNPAD in neighboring Southeast Asian countries such as Vietnam and the Philippines, as well as in the Middle East, to expand overseas export channels.”

Meanwhile, TCM biosciences is currently undergoing a comprehensive stock exchange with NextBT and will become a 100% subsidiary of NextBT after the 17th of next month.

This content was produced with the assistance of AI translation services.